Ocrelizumab signficantly reduces disability progression in MS in studies
9 October 2015 | By Victoria White
Roche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
List view / Grid view
News
BI 655066 cleared skin better than ustekinumab in psoriasis study
8 October 2015 | By Victoria White
Boehringer Ingelheim has reported new results from a Phase II head-to-head psoriasis study that showed superior efficacy of the company’s biologic compound BI 655066 over ustekinumab...
FDA grants Fast Track designation to avelumab for Merkel cell carcinoma
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
Abemaciclib gets Breakthrough Therapy Designation
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
Lemtrada treatment effects maintained over five years in RRMS
8 October 2015 | By Victoria White
Lemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS...
FDA grants HAE drug Ruconest 12-years of exclusivity
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...
Novartis releases long-term efficacy results for Gilenya in MS
8 October 2015 | By Victoria White
The analysis evaluated the proportion of Gilenya patients achieving 'no evidence of disease activity' (NEDA-4) every year over seven years...
NICE says ‘yes’ to pembrolizumab for advanced melanoma
7 October 2015 | By
Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)...
Multiple sclerosis therapeutics market to reach $20b by 2024
7 October 2015 | By Victoria White
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024...
New data shows sustained efficacy of Tecfidera in RRMS
7 October 2015 | By Victoria White
Biogen is to present the data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
FDA approves schizophrenia treatment Aristada
7 October 2015 | By Victoria White
Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...
New data suggests Aubagio slows brain atrophy in RMS
7 October 2015 | By Victoria White
MRI data from Genzyme’s Phase III TEMSO study demonstrate that Aubagio significantly slowed brain atrophy in people with relapsing multiple sclerosis (RMS)...
AcelRx initiates Phase 3 study of pain treatment ARX-04
6 October 2015 | By Victoria White
AcelRx is developing ARX‑04 for the management of moderate-to-severe acute pain in a variety of medically supervised settings, including the emergency room...
FDA grants priority review for HCV treatment Daklinza sNDAs
6 October 2015 | By Victoria White
The applications are for the treatment of patients with chronic HCV coinfected with HIV-1, patients with advanced cirrhosis, and for patients with post-liver transplant recurrence of HCV...
MHRA and India regulators agree deal to improve public safety
6 October 2015 | By Victoria White
A Memorandum of Understanding will increase collaboration between the two countries in the area of medicines and medical devices with the aim of further improving public safety...
